| 2025-02-14 | -0.9 % |
|
| 2025-02-13 | +1 % |
|
| 2025-02-12 | -0.72 % |
|
| 2025-02-11 | +0.1 % |
|
| 2025-02-07 | +0.66 % |
|
| 2025-01-27 | +3.52 % |
|
| 2025-01-24 | +1.47 % |
|
| 2025-01-23 | +4.62 % |
- Abbott Laboratories (ABT) stock rose 4.62% after the company reported fourth-quarter sales of $10.97 billion, which, although slightly below expectations, indicated strong organic growth in its underlying base business, particularly excluding COVID-19 testing-related sales.
- Abbott Laboratories (ABT) stock rose 4.62% following the news that Representative Thomas Kean purchased shares valued between $1,001 and $15,000, signaling investor confidence and potential positive sentiment towards the company.
- Abbott Laboratories (ABT) stock rose 4.62% likely due to a strategic investment and acquisition by Pluri Inc., a biotechnology company that is expanding into the cultivated cacao market, which is expected to strengthen its financial position and growth potential.
- Abbott Laboratories (ABT) stock rose 4.62% after receiving an "outperform" rating and a price target increase from multiple research analysts, indicating strong future performance expectations based on positive quarterly earnings and revenue growth.
- Abbott Laboratories (ABT) stock rose 4.62% likely due to positive investor sentiment around its business stability and growth prospects in the continuous glucose monitoring market, despite fears related to potential political changes in healthcare leadership.
|
| 2025-01-22 | +0.85 % |
|
| 2025-01-21 | +2.92 % |
|
| 2025-01-17 | -0.38 % |
|
| 2025-01-16 | +2.53 % |
|
| 2025-01-15 | -1.7 % |
|
| 2025-01-14 | -0.15 % |
|
| 2025-01-13 | +0.78 % |
|
| 2025-01-06 | -0.69 % |
|
| 2025-01-03 | +0.34 % |
|
| 2024-12-31 | +0.27 % |
|
| 2024-12-24 | +0.39 % |
|
| 2024-12-23 | +0.07 % |
|
| 2024-12-03 | -0.45 % |
|
| 2024-12-02 | -1.65 % |
|
| 2024-11-25 | +0.31 % |
|
| 2024-11-19 | -0.2 % |
|
| 2024-11-14 | -0.61 % |
|
| 2024-11-11 | +0.18 % |
|
| 2024-11-04 | -0.8 % |
|
| 2024-11-01 | +4.61 % |
|
| 2024-10-31 | -0.94 % |
|
| 2024-10-28 | -0.13 % |
|
| 2024-10-24 | -0.4 % |
|
| 2024-10-23 | +0.77 % |
|
| 2024-10-22 | -0.74 % |
|
| 2024-10-21 | -2.01 % |
|
| 2024-10-18 | +1.27 % |
|
| 2024-10-17 | +0.06 % |
|
| 2024-10-16 | +1.53 % |
|
| 2024-10-15 | -1.02 % |
|
| 2024-10-14 | +0.97 % |
|
| 2024-10-11 | +0.43 % |
|
| 2024-10-10 | -0.28 % |
|
| 2024-10-09 | +1.15 % |
|
| 2024-10-08 | +1.12 % |
|
| 2024-10-07 | +0.64 % |
|
| 2024-10-04 | +0.37 % |
|
| 2024-10-02 | +0.07 % |
|
| 2024-10-01 | -0.39 % |
|
| 2024-09-30 | +1.41 % |
|
| 2024-09-27 | -0.27 % |
|
| 2024-09-26 | +0.11 % |
|
| 2024-09-25 | -0.64 % |
|
| 2024-09-24 | -1.28 % |
|
| 2024-09-23 | +0.98 % |
|
| 2024-09-16 | +1.06 % |
- Abbott Laboratories (ABT) stock rose 1.06% recently, likely due to positive investor sentiment buoyed by its strong dividend growth potential, especially in contrast to its spinoff, AbbVie, which has consistently increased its dividends since 2013.
- The article discusses significant insider buy and sell transactions of US stocks, including Abbott Laboratories (ABT), which experienced a 1.06% increase, potentially influenced by the stock's market dynamics following the share sale by its CEO, as insider activities can affect investor sentiment and confidence.
Abbott Laboratories (ABT) stock may have gone up due to overall positive market reactions to recent trading activity, despite the CEO's substantial sale, which could have been seen as a routine transaction rather than a lack of confidence in the company's prospects.
- Abbott Laboratories (ABT) saw a 1.06% increase in stock value, likely due to positive investor sentiment surrounding its strategic growth potential and the performance of its next-generation drugs, despite challenges faced by its spinoff, AbbVie, following the patent expiration of Humira.
|
| 2024-09-13 | -0.37 % |
|
| 2024-09-06 | +0.67 % |
|
| 2024-09-05 | -1.14 % |
|
